# LITESPARK-011 (NCT04586231)

> A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

No report yet. It can be ordered.

- Drugs tested: belzutifan plus lenvatinib
- Indication: advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04586231
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Belzutifan; Lenvatinib; Cabozantinib
- Enrollment: 747
- Primary outcome: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Questions raised in the commentary

_Automated from the 40 newest of 214 indexed sources (Mar 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether the OS findings support a treatment benefit
- Whether benefit varies by prior immunotherapy regimen
- How toxicity trade-offs should shape regimen selection

Also discussed: response durability, real-world benchmarks.

## Indexed commentary on LITESPARK-011 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 164
- YouTube: 22
- Podcasts: 22
- X videos: 5
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=litespark-011-nct04586231

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04586231", "email": "<work email>"}; the inbox owner confirms by the emailed link.